| Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients A Puszkiel, G Noé, P Boudou-Rouquette, C Le-Cossec, J Arrondeau, ... Journal of pharmaceutical and biomedical analysis 139, 30-36, 2017 | 47 | 2017 |
| NF1 alterations in cancers: therapeutic implications in precision medicine JS Giraud, I Bièche, É Pasmant, C Tlemsani Expert Opinion on Investigational Drugs 32 (10), 941-957, 2023 | 15 | 2023 |
| De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics JS Giraud, M Doisne, A Chan Hew Wai, C Majerholc, E Fourn, K Sejean, ... PloS one 15 (9), e0239704, 2020 | 13 | 2020 |
| Prise en compte des critères environnementaux dans la commande publique des produits de santé JS Giraud, F Hamidou, Y Hassani, C Borel, P Le Gonidec Annales Pharmaceutiques Françaises 80 (2), 216-226, 2022 | 6 | 2022 |
| Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: preliminary results A Puszkiel, G Noé, P Boudou-Rouquette, C Le Cossec, J Arrondeau, ... Annals of Oncology 27, vi530, 2016 | 3 | 2016 |
| NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patients JS Giraud, A Jouinot, E Pasmant, C Tlemsani npj Precision Oncology 8 (1), 32, 2024 | 1 | 2024 |
| French national overview of the inclusion of environmental criteria in the public purchasing of health products (drugs and sterile medical devices) JS Giraud, F Hamidou, Y Hassani, C Borel, P Le Gonidec Annales Pharmaceutiques Francaises 80 (2), 216-226, 2021 | 1 | 2021 |
| Évaluation des pratiques de prescription de facteurs de croissance granulocytaire en médecine interne J Giraud, J Giraud, J Alexandra, C Tesmoingt Le Pharmacien Hospitalier et Clinicien 54 (1), 85, 2019 | 1 | 2019 |
| NF1 mutations in lung adenocarcinoma preclinical models and potential targeted therapies: The crucial role of the RAS-MAPK pathway JS Giraud, D Gorret, M Ye, D Lallemand, WC Reinhold, D Decaudin, ... Cancer Research 85 (8_Supplement_1), 6709-6709, 2025 | | 2025 |
| Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial (Oct, oyae213, 2025) JS Giraud, V Korb-Savoldelli, G Perrin, A Jouinot, B Sabatier, R Batista, ... ONCOLOGIST 30 (1), 2025 | | 2025 |
| Évaluation pharmaceutique des risques de prescription des anticoagulants oraux directs chez le patient atteint de cancer JS Giraud, M Berge, J Sardelli, P Boudou-Rouquette, R Batista, ... Le Pharmacien Clinicien 59 (4), 452-466, 2024 | | 2024 |
| Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial JS Giraud, V Korb-Savoldelli, G Perrin, A Jouinot, B Sabatier, R Batista, ... The Oncologist, oyae213, 2024 | | 2024 |
| Feedback with the ApotecaChemo® robot: management of microbiological contamination É Kobylarz, S Busse, A Hammadi, JS Giraud, A Acramel, C Pagès, ... Journal de Pharmacie Clinique 43 (3), 115-120, 2024 | | 2024 |
| Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report M Berge, JS Giraud, S De Percin, A Puszkiel, A Thomas-Schoemann, ... Cancer Chemotherapy and Pharmacology 93 (5), 519-521, 2024 | | 2024 |
| 1ISG-010 Economic impact of the clinical pharmacist on the reduction of drug-related problems before the initiation of an anti-tumour treatment–a prospective multicentre trial JS Giraud, V Savoldelli, G Perrin, B Sabatier, R Batista, F Goldwasser, ... European Journal of Hospital Pharmacy 31 (Suppl 1), A11-A11, 2024 | | 2024 |
| 4CPS-125 Pharmaceutical consultations dedicated to direct oral anticoagulants for cancer patients: a single-centre prospective study JS Giraud, T Inouri, P Ripoche, C Moine-Picard, R Batista, F Goldwasser, ... European Journal of Hospital Pharmacy 31 (Suppl 1), A111-A112, 2024 | | 2024 |
| Retour d’expérience avec le robot ApotecaChemo®: management de la contamination microbiologique É Kobylarz, S Busse, A Hammadi, JS Giraud, A Acramel, C Pagès, ... Journal de Pharmacie Clinique 43 (3), 115-120, 2024 | | 2024 |
| Évaluation des performances d’une pompe de remplissage monovoie Medimix Vigo® A Citerne, M Robert, JS Giraud, AL Raso, S Alves, N Vaillant, D Sankhare, ... Le Pharmacien Clinicien 58 (1), e11, 2023 | | 2023 |
| Rôle du pharmacien dans l’évaluation du risque de prescription des anticoagulants oraux directs chez les patients atteints de cancer M Berge, J Sardelli, JS Giraud, A Jouinot, A Thomas-Schoemann Le Pharmacien Clinicien 58 (1), e8, 2023 | | 2023 |
| Acceptabilité du remplacement des associations fixes d’antirétroviraux (ARV) par des traitements comportant des génériques d’analogues nucléosidiques JS Giraud, M Doisne, A Chan-Hew-Wai, C Majerholc, K Sejean, B Bonan, ... Médecine et Maladies Infectieuses 49 (4), S144, 2019 | | 2019 |
